Avalon GloboCare Corp. (ALBT)
| Market Cap | 5.31M |
| Revenue (ttm) | 1.23M |
| Net Income (ttm) | -9.23M |
| Shares Out | 11.00M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,198 |
| Open | 0.473 |
| Previous Close | 0.475 |
| Day's Range | 0.440 - 0.500 |
| 52-Week Range | 0.390 - 6.050 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2023 |
About ALBT
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development sta... [Read more]
Financial Performance
In 2022, ALBT's revenue was $1.20 million, a decrease of -13.57% compared to the previous year's $1.39 million. Losses were -$11.93 million, 31.2% more than in 2021.
Financial StatementsNews
Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US
FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory...
Apple Approves Use of Avalon GloboCare's KetoAir Mobile Application
KetoAir™ Mobile Application Launches in Apple App Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“...
Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device
FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laborator...
Avalon's Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis
New Proprietary Testing Method Makes Tuberculosis Diagnosis Easier and Faster New Test Method Expected to Generate Revenue in 2023 FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Co...
Avalon's Laboratory Services MSO Announces Expansion into Arizona
New Wholly Owned Lab “Veritas Laboratory” of Arizona, Anticipated to Generate Revenue in 2023 Engages Former Congressman Barry M. Goldwater Jr. To Expand Insurance Coverage and Grow Lab Footprint FREE...
Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
DE Laboratory in Texas Performs 1,500 Lab Tests Per Month with Focus on Toxicology and Wellness Testing; Expansion Underway DE Laboratory in Texas Performs 1,500 Lab Tests Per Month with Focus on Toxi...
Avalon GloboCare's Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States
MSA Signed with GeneX Laboratory, an In-Network Laboratory Licensed in Multiple States Including Medicare and Medicaid Laboratory Services MSO will be the Exclusive Testing Provider for Toxicology Tes...
Avalon GloboCare Provides Update on New Commercial Strategy
Company Continues to Implement Major Change in Strategy Focused on Acquiring and Operating Accretive Revenue Generating Laboratories and Related Commercialized Products
Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022
40% Profit Sharing Arrangement with Laboratory Services MSO is Expected to Result in Significant Future Cash Flow to the Company 40% Profit Sharing Arrangement with Laboratory Services MSO is Expected...
Avalon GloboCare to Participate in the 35th Annual Roth Conference
FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy a...
Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement
Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Patent Jointly Filed with the Massachusetts Institute of Technology (MIT) Patent Jointly Filed with the Massachusetts Institute of Technology (MIT)
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
Ms. Felix's Appointment Will Support New Roll-Up Strategy Targeting Toxicology Labs, Including Within the Addiction Sector Ms. Felix's Appointment Will Support New Roll-Up Strategy Targeting Toxicolog...
Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients Enabling the Development and Commercialization of Companion Diagnostics and ...
Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company's Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
Newly issued preferred stock convertible at a minimum of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up
Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, reminds investors ...
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022